These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38736552)

  • 1. Assessment of the impact of residual tumors at different sites post-neoadjuvant chemotherapy on prognosis in breast cancer patients and development of a disease-free survival prediction model.
    Yang H; Ruan Y; Sun Y; Wang P; Qiao J; Wang C; Liu Z
    Ther Adv Med Oncol; 2024; 16():17588359241249578. PubMed ID: 38736552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Construction of a nomogram prediction model for pathological complete response (pCR) of ipsilateral supraclavicular lymph node after neoadjuvant chemotherapy for breast cancer with first diagnosis of ipsilateral supraclavicular lymph node metastasis].
    Lyu MH; Jiao DC; Wu JZ; Tian PQ; Ma YZ; Liu ZZ; Chen XC
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):160-166. PubMed ID: 35184460
    [No Abstract]   [Full Text] [Related]  

  • 3. A Nomogram to Predict Disease-Free Survival Following Neoadjuvant Chemotherapy for Triple Negative Breast Cancer.
    Zhu M; Liang C; Zhang F; Zhu L; Chen D
    Front Oncol; 2021; 11():690336. PubMed ID: 34745934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K).
    Han R; Ma Y; Liu Z; Li C; Li S; Kong X; Han M; Liu Y; Geng C
    Transl Breast Cancer Res; 2022; 3():24. PubMed ID: 38751546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.
    Lai J; Wang H; Peng J; Chen P; Pan Z
    Cancer Manag Res; 2018; 10():2347-2356. PubMed ID: 30122984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study.
    Wang MD; Duan FF; Hua X; Cao L; Xia W; Chen JY
    Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():831848. PubMed ID: 35320931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis.
    Maimaitiaili A; Fan Z; Zhang J; Wang Y; Shi B; Zheng J; Li G; Zhao Y; Pu S; He J; Qu F; Zhang H
    Ther Adv Med Oncol; 2024; 16():17588359241248318. PubMed ID: 38716480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy.
    Hou N; Wu J; Xiao J; Wang Z; Song Z; Ke Z; Wang R; Wei M; Xu M; Wei J; Qian X; Xu X; Yi J; Wang T; Zhang J; Li N; Fan J; Hou G; Wang Y; Wang Z; Ling R
    ESMO Open; 2021 Oct; 6(5):100269. PubMed ID: 34537675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomograms for Predicting Disease-Free Survival Based on Core Needle Biopsy and Surgical Specimens in Female Breast Cancer Patients with Non-Pathological Complete Response to Neoadjuvant Chemotherapy.
    Lan A; Li H; Chen J; Shen M; Jin Y; Dai Y; Jiang L; Dai X; Peng Y; Liu S
    J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram for predicting axillary lymph node pathological response in node-positive breast cancer patients after neoadjuvant chemotherapy.
    Wang W; Wang X; Liu J; Zhu Q; Wang X; Wang P
    Chin Med J (Engl); 2021 Dec; 135(3):333-340. PubMed ID: 35108228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a nomogram incorporating axillary lymph node ratio to predict survival in node-positive breast cancer patients after neoadjuvant chemotherapy.
    Lai J; Pan Z; Chen P; Ye G; Chen K; Su F
    Jpn J Clin Oncol; 2019 Jan; 49(1):22-28. PubMed ID: 30508184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.
    Diaz-Botero S; Espinosa-Bravo M; Gonçalves VR; Esgueva-Colmenarejo A; Peg V; Perez J; Cortes J; Rubio IT
    Ann Surg Oncol; 2016 Nov; 23(12):3831-3837. PubMed ID: 27357178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
    Pang J; Wang S; Liao L; Liu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy.
    Chen L; Huang S; Liu Q; Kong X; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
    Front Immunol; 2022; 13():849468. PubMed ID: 35669769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.
    Kim JY; Park HS; Kim S; Ryu J; Park S; Kim SI
    Medicine (Baltimore); 2015 Oct; 94(43):e1720. PubMed ID: 26512562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.